Dthera

Nerve cells affected by Alzheimer's disease
Digital therapeutics startup Dthera Sciences was sunk by Alzheimer's drug failures, CMS reimbursement limitations
By Dave Muoio | 04:04 pm | April 01, 2021
Former CEO Ed Cox tells the story of Dthera Sciences and outlines how the digital therapeutics landscape has shifted since his company's heyday.
FDA grants digital therapeutic for Alzheimer's symptoms Breakthrough Device designation
By Dave Muoio | 04:29 pm | August 23, 2018
As laid out in the 21st Century Cures Act, the Breakthrough Devices Program looks to streamline new medical technologies that offer improved treatment for serious diseases.